We are a leading healthcare campus encompassing all fields of health: from healthcare and research to teaching and management.
Professionalism, commitment and research by professionals on the Campus are the key elements in offering patients excellent care.
We are committed to research as a tool to provide solutions to the daily challenges we face in the field of medical healthcare.
Thanks to our healthcare, teaching and research potential, we work to incorporate new knowledge to generate value for patients, professionals and the organization itself.
We generate, transform and transmit knowledge in all areas of the health sciences, helping to train the professionals of the future.
We are defined by our vocation for communication. We invite you to share everything that happens at Vall d'Hebron Barcelona Hospital Campus, and our doors are always open.
Hospital donations
Research donations
The Vall d’Hebron Institute of Research’s Paediatric Cancer and Hematological Diseases Research Group Achieves Promising Results for Acute Graft-Versus-Host Disease.
A new study conducted by the Pediatric Cancer and Hematological Diseases Research Group at Vall d’Hebron Institute of Research (VHIR) has demonstrated that the drug Ruxolitinib, already used in adults, is also effective and safe for treating paediatric patients with acute graft-versus-host disease (aGVHD).
The aGVHD occurs when a person receives a bone marrow or hematopoietic stem cell transplant and the donor’s new immune system attacks the recipient's body. Symptoms can include skin rashes, liver damage, and severe gastrointestinal problems, potentially leading to significant morbidity and, in extreme cases, death.
The study, named REACH4, is published in Blood, from the American Society of Hematology (NCT03491215). It is particularly important as it focuses on paediatric patients who had not received prior treatment or had not responded to steroids, the standard treatment for this condition. The research was conducted across multiple medical centres, allowing for a broader evaluation of the results. Ruxolitinib was administered based on age: patients aged 12 to 18 received 10 mg twice daily, those aged 6 to 12 received 5 mg twice daily, and those aged 2 to 6 received 4 mg twice daily.
The results of the REACH4 study are positive and promising. The doses administered to the different age groups were confirmed to be effective. Additionally, the overall response rate was 84.4% of patients on day 28 and 66.75% on day 56, indicating that the majority of patients achieved significant improvement, regardless of age group or previous steroid treatment. Furthermore, Ruxolitinib’s effect was shown to be durable.
The most common adverse effects observed were anaemia, decreased neutrophil count, and a reduced overall white blood cell count. No other adverse effects were noted beyond those already observed with Ruxolitinib in other populations. This suggests that Ruxolitinib is a safe treatment for these patients.
“The aGVHD is a devastating complication that can limit treatment options for children who have received a bone marrow transplant. The fact that Ruxolitinib has shown such high efficacy in this study is a significant breakthrough in the treatment of this disease in paediatrics,” says Dr. Cristina Díaz de Heredia Rubio, Head of the Paediatric Oncology and Haematology Section and Director of the Hematopoietic Stem Cell Transplant Program at Vall d’Hebron University Hospital and principal investigator of the REACH4 study conducted by VHIR.
Although the results offer new hope for parents and families facing aGVHD in paediatric patients, further studies will be needed for approval.
Paediatric Oncology and Haematology, Children's Hospital and Woman's Hospital
Paediatrics, Children's Hospital and Woman's Hospital
The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”. Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health). Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information. Legal basis: Consent of the data subject. Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen. Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time. Source: The data subject. Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.